What this workflow supports and what it does not

A concordant, confounder-addressed, two-system abnormal screen-mix-confirm pattern supports evidence of a phospholipid-dependent inhibitor consistent with LA. It does not support naming APS. APS classification requires clinical criteria in addition to laboratory findings, and even the laboratory portion requires persistence, two positive tests at least 12 weeks apart, which a single specimen cannot establish.

Every ratio cutoff and reference range used here is a value assigned for this case, not a transferable reference interval. ISTH recommends deriving an in-house cutoff from at least 120 normal individuals or documenting a validated manufacturer-cutoff transfer; no analyzer, reagent, software version, or current instructions for use is declared here, and a real report must use the exact locally validated ones.

Method and timing caveats remain even in a clean case like this one: a corrected mix does not exclude a weak LA, acute-phase markers were not available here and can shift results in either direction depending on the reagent, and testing during active anticoagulant exposure, especially a DOAC, can make the whole pattern uninterpretable regardless of how the numbers look.

Release language separates what the assay measures, a phospholipid-dependent clotting time pattern, from what the result may mean clinically, and it never substitutes for the persistence and clinical correlation that classification requires.